US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DelMar Pharmaceuticals

1.34

0.0000

Volume:- -

Turnover:- -

Market Cap:15.32M

PE:-1.41

High:1.34

Open:1.34

Low:1.34

Close:1.34

52wk High:1.53

52wk Low:0.3800

Shares:11.43M

Float Shares:10.64M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.9481

EPS(LYR):-3.1571

ROE:-316.71%

ROA:-136.86%

PB:-14.14

PE(LYR):-0.42

Loading ...

Overview Company News Filings

Company Profile

Company Name:

DelMar Pharmaceuticals

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.delmarpharma.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in San Diego, California.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DMPI/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"DMPI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMPI\",,,,,undefined,":{"symbol":"DMPI","market":"US","secType":"STK","nameCN":"DelMar Pharmaceuticals","latestPrice":1.34,"timestamp":1597867200000,"preClose":1.34,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":10639578,"shares":11429228,"eps":-0.948087,"marketStatus":"Trading","change":0,"latestTime":"02-17 11:43:19 EST","open":1.34,"high":1.34,"low":1.34,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.948087,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771362000000},"marketStatusCode":2,"symbolChange":{"newSymbol":"KTRA","executeDate":"2020-08-20"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.34,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMPI\",,,,,undefined,":{"symbol":"DMPI","floatShares":10639578,"roa":"-136.86%","roe":"-316.71%","lyrEps":-3.157135,"shares":11429228,"dividePrice":0,"high":1.34,"amplitude":0,"preClose":1.34,"low":1.34,"week52Low":0.38,"pbRate":"-14.14","week52High":1.53,"institutionHeld":0,"latestPrice":1.34,"eps":-0.948087,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.948087,"open":1.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DMPI\",params:#limit:5,,,undefined,":[{"date":"2020-09-08","symbol":"DMPI","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2020/06","expectedEps":-0.09,"defaultRemindTime":1599552000000,"name":null,"time":"","dateTimestamp":1599537600000,"actualEps":null},{"market":"US","date":"2020-08-20","symbol":"DMPI","oldSymbol":"DMPI","defaultRemindTime":1597930200000,"newSymbol":"KTRA","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1597896000000},{"market":"US","date":"2020-05-13","symbol":"DMPI","fiscalQuarterEnding":"2020/03","expectedEps":-0.05,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1589342400000,"reportTimeType":"pre","actualEps":-0.17},{"market":"US","date":"2020-02-13","symbol":"DMPI","fiscalQuarterEnding":"2019/12","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1581570000000,"reportTimeType":"pre","actualEps":-0.15},{"market":"US","date":"2019-11-13","symbol":"DMPI","fiscalQuarterEnding":"2019/09","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1573621200000,"reportTimeType":"pre","actualEps":-0.21}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DMPI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DMPI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DMPI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DMPI","date":"2020-08-18","current":-1.413372,"percent":0.024561,"low":-2.034217,"twenty":-1.087381,"median":-0.842447,"eighty":-0.608463,"high":-0.314917,"avg":-0.906537,"sd":0.327882,"marketCap":13291196},"quantilePoints":[],"updateTime":1771346599953},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.delmarpharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0125},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.0595},{"period":"1year","weight":0.1181},{"period":"ytd","weight":-0.0002}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in San Diego, California.","exchange":"NASDAQ","name":"DelMar Pharmaceuticals","nameEN":"DelMar Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"DMPI\",market:\"US\",,,undefined,":null}}